Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Contineum Therapeutics

Request full access

Creating a portfolio of first-in-class small molecules in neuro-regeneration

San Diego, United StatesFounded 2017Biotech & Life Sciences

About Contineum Therapeutics

Pipeline Therapeutics is a biotechnology company focused on developing next-generation neuro-regenerative therapies. Located near the University of California, San Diego, the company operates in the biopharmaceutical sector, targeting neurological disorders such as hearing loss, multiple sclerosis (MS), and other synaptopathies and demyelinated diseases. Pipeline Therapeutics serves patients and healthcare providers by advancing first-in-class therapeutics aimed at synaptogenesis (the formation of synapses), remyelination (the repair of myelin sheaths around nerves), and axonal repair (restoring function in damaged axons). The business model revolves around research and development (R&D) of small molecules and biologics, which are then licensed or sold to larger pharmaceutical companies or brought to market through strategic partnerships. Revenue is generated through licensing agreements, milestone payments, and royalties from commercialized products. The company is led by Carmine Stengone, President and CEO, and Daniel Lorrain, PhD, Chief Scientific Officer, both of whom bring extensive experience in biotech and pharmaceutical development.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2024
Employees
56
Open positions
None listed
Dealroom signal
80.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITYOther financing Dec 2025 $90M — Undisclosed ↗
IPOOther financing Apr 2024 $110M $110M Undisclosed ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Contineum Therapeutics website traffic

Latest recorded traffic for Contineum Therapeutics is 1.1K monthly website visits, up 292.9% over the last three months. Contineum Therapeutics's team grew 3.7% over the past year.

Latest monthly visits1.1K 3-month web change+292.9% 1-year team growth+3.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Contineum Therapeutics in the San Diego ecosystem

Live from Dealroom

The Contineum Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Sectoral Asset Management
  • Versant Ventures
  • Brace Pharma
  • Hadean Ventures
  • RBV Capital

Series B and later6 investors entered at this stage

Other known investors1 additional known investor

  • Scripps Translational Science Institute
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Contineum Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Contineum Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.